Subscribe
The latest psychology and neuroscience discoveries.
My Account
  • Mental Health
  • Social Psychology
  • Cognitive Science
  • Psychopharmacology
  • Neuroscience
  • About
No Result
View All Result
PsyPost
PsyPost
No Result
View All Result
Home Exclusive Psychopharmacology

Exposure to cannabinoids may exacerbate the psychological consequences of trauma

by Eric W. Dolan
July 30, 2018
in Psychopharmacology
(Photo credit: Sebastian Kaulitzki)

(Photo credit: Sebastian Kaulitzki)

Share on TwitterShare on Facebook

Synthetic cannabinoids can increase depression- and anxiety-like behaviors in a rodent model of trauma, according to new research in European Neuropsychopharmacology.

“Brenda Sbarski, one of my master students, was very much interested to find out how pre-trauma exposure to cannabinoids affect the response to a traumatic event. All of our studies were conducted on rats with no prior exposure to cannabinoids (before the trauma) and she thought that this may not represent the human condition correctly,” said study author Irit Akirav of the University of Haifa.

The researchers were interested in learning whether chronic exposure to a cannabinoid receptor agonist before experiencing trauma would have a therapeutic effect or would exacerbate the negative consequences of trauma.

In their experiments, rats were administered the synthetic CB1/2 receptor agonist WIN55,212–2 for twelve days before being subjected to an inescapable electric shock.

Exposure to the cannabinoid receptor agonist enhanced fear retrieval and impaired fear extinction, and also increased immobility in a forced swimming test — behaviors that reflect anxiety and depression, respectively. But it was also found to have a therapeutic effect in a startle test.

The key finding is that “chronic exposure to drugs that activate CB1 receptors before being exposed to a traumatic event might have deleterious effects on the emotional response to the trauma (compared to subjects that were not expose to cannabinoids before the trauma),” Akirav told PsyPost.

“We need to study what happens when we administer cannabinoids after trauma exposure to subjects that were already exposed to cannabinoids before trauma exposure. Will they need a different treatment than the non pre-trauma exposed subjects?”

“The effects may be specific to CB1 receptor activation,” she added. “It could be that other cannabinoids (not directly activating the CB1 receptor) may have different (better?) effects on the response to the trauma.”

The study, “Chronic exposure to cannabinoids before an emotional trauma may have negative effects on emotional function“, was authored by Brenda Sbarski and Irit Akirav.

TweetSendScanShareSendPinShareShareShareShareShare

RELATED

ADHD drug shows promise in treating some symptoms of Alzheimer’s disease
Depression

Withdrawal symptoms are common after stopping antidepressants

May 23, 2025

Researchers analyzed data from 35 studies and found that over 40% of antidepressant users experienced withdrawal symptoms, including dizziness, irritability, and mood disturbances. The findings suggest the need for better tapering strategies and patient education.

Read moreDetails
Pills spilling out of a bottle on a table
ADHD

Common blood pressure drug shows promise for treating ADHD symptoms

May 22, 2025

Amlodipine, typically used for hypertension, may have brain-based effects that make it a candidate for ADHD treatment, according to new research.

Read moreDetails
Psychedelic’s anti-anxiety effects can be separated from hallucinations by targeting specific brain circuits
Neuroimaging

Psychedelic’s anti-anxiety effects can be separated from hallucinations by targeting specific brain circuits

May 19, 2025

A mouse study published in Science shows that stimulating a specific set of brain cells activated by a psychedelic drug can reduce anxiety without triggering hallucination-like behavior, pointing to new possibilities for targeted mental health treatments.

Read moreDetails
New study sheds light on which post-psychedelic difficulties last longest and what helps people cope
Psychedelic Drugs

New study sheds light on which post-psychedelic difficulties last longest and what helps people cope

May 18, 2025

While many praise psychedelics for their therapeutic power, new research reveals that some users face long-lasting psychological challenges. This study explores the most common difficulties and the coping strategies people turn to for support and recovery.

Read moreDetails
Young adults who drink heavily report more romantic highs and lows
Addiction

Young adults who drink heavily report more romantic highs and lows

May 18, 2025

A new study of heavy-drinking young adults found that drinking more on a given day was linked to both regretted and positive romantic or sexual experiences. For women, using cannabis alongside alcohol appeared to reduce the likelihood of regret.

Read moreDetails
Amphetamine scrambles the brain’s sense of time by degrading prefrontal neuron coordination
Neuroimaging

Amphetamine scrambles the brain’s sense of time by degrading prefrontal neuron coordination

May 18, 2025

Researchers have found that amphetamine alters how the brain processes time, increasing variability in the activity of neurons that encode temporal information. The study provides insight into how the drug affects executive function and decision-making at the neural level.

Read moreDetails
Inhaled DMT produces rapid and lasting antidepressant effects in treatment-resistant depression
Ayahuasca

Inhaled DMT produces rapid and lasting antidepressant effects in treatment-resistant depression

May 17, 2025

Vaporized DMT produced fast and lasting improvements in depression symptoms and suicidal ideation, according to a new phase 2a trial, highlighting its potential as a scalable, non-invasive alternative to conventional and long-acting psychedelic treatments for severe depression.

Read moreDetails
Single dose of 5-MeO-DMT alters gene expression in brain and reduces anxiety-like behavior in stressed mice
Psychedelic Drugs

Single dose of 5-MeO-DMT alters gene expression in brain and reduces anxiety-like behavior in stressed mice

May 16, 2025

New findings reveal that 5-MeO-DMT, a fast-acting psychedelic, can change brain gene activity and reduce anxiety-related behavior in stressed mice, offering promising insights into its lasting effects and potential use in treating anxiety disorders.

Read moreDetails

SUBSCRIBE

Go Ad-Free! Click here to subscribe to PsyPost and support independent science journalism!

STAY CONNECTED

LATEST

Neuroscientists challenge “dopamine detox” trend with evidence from avoidance learning

Non-right-handedness is more common across multiple mental health conditions

Withdrawal symptoms are common after stopping antidepressants

Anxious attachment linked to depression spillover in romantic relationships, study finds

Scientists find 16 new Alzheimer’s-linked genes using multi-ancestry genome data

Groundbreaking AI model uncovers hidden patterns of political bias in online news

Gut bacteria can influence how brain proteins are modified by carbohydrates

“Tiger mom” parenting boosts teens’ cognitive skills but undermines emotional development, study suggests

         
       
  • Contact us
  • Privacy policy
  • Terms and Conditions
[Do not sell my information]

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe
  • My Account
  • Cognitive Science Research
  • Mental Health Research
  • Social Psychology Research
  • Drug Research
  • Relationship Research
  • About PsyPost
  • Contact
  • Privacy Policy